PNC-27 Pen

PNC-27 is a synthetic peptide derived from a segment of the p53 protein fused with a membrane-penetrating peptide sequence. In laboratory environments, it is utilised in research involving peptide–membrane interactions and p53-associated signalling pathways.

PNC-27 is a synthetic peptide engineered from a segment of the p53 protein, which is widely studied in research involving cellular signalling pathways. The peptide is fused to a membrane-penetrating domain, allowing it to be used in controlled experimental models examining peptide interaction with cellular membranes.

Chemical reference information: Sequence: p53 residues 12–26 linked to a membrane-penetrating sequence. These reference identifiers describe the formulation; the batch-specific analytical record identifies the supplied material.

Reference conditions for unreconstituted research material are −20°C with moisture and direct light excluded. Use the storage instructions on the supplied batch record for the actual presentation, and record any change of physical state or storage conditions.

Where laboratory preparation is required, use an appropriate validated solvent and aseptic peptide-handling procedure. Solvent compatibility, final concentration, and post-preparation storage depend on the specific formulation and experimental protocol. The catalog strength is the compound amount, not the concentration of a prepared solution.

NORVEXA Bioscience batch documentation can be requested using the printed reference and lot number. Review identity, analytical purity, presentation, and handling specifications before including a material in a laboratory workflow.

PNC-27 5 mg is offered as a NORVEXA research pen. The selected strength refers to the compound content of this pen reference. Request the matching batch record for identity, analytical specifications, and presentation details.

Reference conditions for unreconstituted research material are −20°C with moisture and direct light excluded. Use the storage instructions on the supplied batch record for the actual presentation, and record any change of physical state or storage conditions.

Where laboratory preparation is required, use an appropriate validated solvent and aseptic peptide-handling procedure. Solvent compatibility, final concentration, and post-preparation storage depend on the specific formulation and experimental protocol. The catalog strength is the compound amount, not the concentration of a prepared solution.

NORVEXA Bioscience batch documentation can be requested using the printed reference and lot number. Review identity, analytical purity, presentation, and handling specifications before including a material in a laboratory workflow.

Sequence

p53 residues 12–26 linked to a membrane-penetrating sequence

Include the printed batch reference when requesting your certificate of analysis. The record applies to the batch supplied to your laboratory.